Baxter Attains Approval for Hemophilia Treatment

The company has received the go-ahead for ADVATE recombinant human coagulation factor VIII for injection.

Baxter International Inc. today announced the approval of ADVATE [Recombinant Human Coagulation Factor VIII for injection] for the control and prophylaxis of bleeding episodes in individuals with hemophilia A (congenital factor VIII deficiency) in China by the State Food and Drug Administration (SFDA). It is estimated that more than 50,000 people in China are living with hemophilia A.

No votes yet

Labeling Error Spurs Recall of Baxter Biologic

Baxter Healthcare Corp. has recalled vials of GAMMAGARD LIQUID 10%, 20g, due to incorrect manufacturing and expiration dates.

GAMMAGARD LIQUID, [Immune Globulin Intravenous (Human)] 10%, 20g size
Product Code 1502797
NDC # 0944-2700-06
Baxter Healthcare Corp.
Westlake Village, CA

No votes yet
Syndicate content